| Sacituzumab govitecan in metastatic triple-negative breast cancer A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ... New England journal of medicine 384 (16), 1529-1541, 2021 | 847 | 2021 |
| Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer ISPY Investigators N Engl J Med 375 (1), 23-34, 2016 | 585* | 2016 |
| Prevalence of homologous recombination–related gene mutations across multiple cancer types AL Heeke, MJ Pishvaian, F Lynce, J Xiu, JR Brody, WJ Chen, TM Baker, ... JCO precision oncology 2, 1-13, 2018 | 348 | 2018 |
| Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer S Vinayak, SM Tolaney, L Schwartzberg, M Mita, G McCann, AR Tan, ... JAMA oncology 5 (8), 1132-1140, 2019 | 331 | 2019 |
| Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer … M Radovich, G Jiang, BA Hancock, C Chitambar, R Nanda, C Falkson, ... JAMA oncology 6 (9), 1410-1415, 2020 | 196 | 2020 |
| Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study F Lynce, A Barac, X Geng, C Dang, AF Yu, KL Smith, C Gallagher, ... Breast cancer research and treatment 175, 595-603, 2019 | 127 | 2019 |
| TOPACIO/Keynote-162: Niraparib+ pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. S Vinayak, SM Tolaney, LS Schwartzberg, MM Mita, GAL McCann, ... Journal of Clinical Oncology 36 (15_suppl), 1011-1011, 2018 | 92 | 2018 |
| Management of cardiovascular disease in women with breast cancer R Barish, F Lynce, K Unger, A Barac Circulation 139 (8), 1110-1120, 2019 | 69 | 2019 |
| How far do we go with genetic evaluation? Gene, panel, and tumor testing F Lynce, C Isaacs American Society of Clinical Oncology Educational Book 36, e72-e78, 2016 | 64 | 2016 |
| Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative … V Diéras, R Weaver, SM Tolaney, A Bardia, K Punie, A Brufsky, HS Rugo, ... Cancer Research 81 (4_Supplement), PD13-07-PD13-07, 2021 | 63 | 2021 |
| CDK4/6 inhibitors in breast cancer therapy: current practice and future opportunities F Lynce, AN Shajahan-Haq, SM Swain Pharmacology & therapeutics 191, 65-73, 2018 | 63 | 2018 |
| Racial disparities in the molecular landscape of cancer EI Heath, F Lynce, J Xiu, A Ellerbrock, SK Reddy, E Obeid, SV Liu, ... Anticancer Research 38 (4), 2235-2240, 2018 | 54 | 2018 |
| Genomic disparities in breast cancer among Latinas F Lynce, KD Graves, L Jandorf, C Ricker, E Castro, L Moreno, B Augusto, ... Cancer control 23 (4), 359-372, 2016 | 51 | 2016 |
| Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial. L Spring, SM Tolaney, NV Desai, G Fell, L Trippa, AH Comander, ... Journal of Clinical Oncology 40 (16_suppl), 512-512, 2022 | 35 | 2022 |
| Surgical standards for management of the axilla in breast cancer clinical trials with pathological complete response endpoint JC Boughey, MD Alvarado, RB Lancaster, W Fraser Symmans, R Mukhtar, ... NPJ Breast Cancer 4 (1), 26, 2018 | 34 | 2018 |
| SAFE‐HEaRt: rationale and design of a pilot study investigating cardiac safety of HER2 targeted therapy in patients with HER2‐positive breast cancer and reduced left … F Lynce, A Barac, MT Tan, FM Asch, KL Smith, C Dang, C Isaacs, ... The oncologist 22 (5), 518-525, 2017 | 34 | 2017 |
| First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb),±cemiplimab in patients (pts) with advanced malignancies. KP Papadopoulos, NJ Lakhani, ML Johnson, H Park, D Wang, TA Yap, ... Journal of Clinical Oncology 37 (15_suppl), 2508-2508, 2019 | 33 | 2019 |
| BRE12-158: A postneoadjuvant, randomized phase II trial of personalized therapy versus treatment of physician's choice for patients with residual triple-negative breast cancer BP Schneider, G Jiang, TJ Ballinger, F Shen, C Chitambar, R Nanda, ... Journal of clinical oncology 40 (4), 345-355, 2022 | 26 | 2022 |
| Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway AL Heeke, J Xiu, A Elliott, WM Korn, F Lynce, PR Pohlmann, C Isaacs, ... Breast Cancer Research and Treatment 184, 265-275, 2020 | 25 | 2020 |
| Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer F Lynce, JT Williams, MM Regan, CA Bunnell, RA Freedman, SM Tolaney, ... Cancer Chemotherapy and Pharmacology 87, 673-679, 2021 | 24 | 2021 |
Sara TolaneyDana-Farber Cancer InstituteAdresse e-mail validée de dfci.harvard.edu
